TCA 35% versus phenol 88% in treatment of alopecia areata

A randomized controlled trial of TCA 35% versus phenol 88% in treatment of alopecia areata

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201804003334544

Enrollment

Registered

2018-04-18

Start date

2017-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases Alopecia areata

Interventions

TCA 35%

Phenol 88%

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with multifocal patchy AA of the scalp (> 2 patches). Both genders. Age group > 4 years old.

Exclusion criteria

Exclusion criteria: Any subject with any variant of AA other than the multifocal patchy variant. Any subject with end-stage cicatrized AA. Any subject who is currently experiencing significant spontaneous regrowth of terminal hair. Any subject treated with a topical, intralesional or systemic agent likely to cause regrowth in AA within one month prior to enrollment in the study. Any subject with a dermatological condition affecting the scalp other than AA: e.g. psoriasis, eczema. Any subject with psychiatric illness or psychological state interfering with compliance or influencing the expectation of the patient.

Design outcomes

Primary

Measure	Time frame
Efficacy of TCA 35% and phenol 88% in the treatment of alopecia areata	—

Secondary

Measure	Time frame
tolerability of TCA 35% and phenol 88% in alopecia areata treatment	—

Countries

Egypt

Contacts

Public ContactRiham Mohye Eldin

Resident of Dermatology / Cairo University

dr.rm.sc@gmail.com+20106239360

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026